Antidepresanların ilaç ilişkili hareket bozuklukları ve cinsel yan etkiler açısından karşılaştırılması

Year 2021, , 610 - 620, 30.06.2021

Zeynep Namlı , Lut Tamam , Mehmet Emin Demirkol , Mahmut Onur Karaytuğ , Kerim Uğur , Özge Eriş

https://doi.org/10.17826/cumj.865933

Abstract

Amaç: Çalışmamızda farklı antidepresan gruplarının cinsel yan etkiler, daha az bilinen uyku bruksizmi ve nörolojik yan etkiler açısından karşılaştırılması amaçlanmıştır.
Gereç ve Yöntem: Çalışmanın örneklem grubunu 18-50 yaş aralığında, depresif bozukluklar ve/veya anksiyete bozuklukları tanısı ile ayaktan tedavi gören, 1 aydan uzun süredir antidepresan monoterapisi alan 406 hasta oluşturmaktadır. Tüm hastalara; sosyodemografik veri formu, Hamilton Depresyon Ölçeği (HAM-D), Hamilton Anksiyete Ölçeği (HAM-A), UKU Yan Etki Değerlendirme Ölçeği nörolojik yan etkiler bölümü, Arizona Cinsel Yaşantılar Ölçeği (ACYÖ) ve Morisky İlaç Uyum Ölçeği uygulanmıştır. Kullanılan antidepresanlar; seçici serotonin geri alım inhibitörleri (SSGİ), serotonin norepinefrin geri alım inhibitörleri (SNGİ ve vortioksetin olmak üzere üç gruba ayrılarak karşılaştırılmıştır.
Bulgular: YAB tanılı hastalarda SNGİ kullananların UKU nörolojik yan etkiler ortalama puanı SSGİ kullananlardan anlamlı olarak yüksek belirlendi. Depresif bozukluk tanılı hastalarda; ilaç tedavisine yeterli uyum sırasıyla %91.3 oranında vortioksetin, % 73.8 oranında SSGİ ve %50 oranında SNGİ kullanan hastalarda belirlendi ve üç grup arasındaki fark istatistiksel olarak anlamlıydı.
Sonuç: Antidepresan ilaç grupları bazı yan etkiler ve tedavi uyumu açısından birbirinden farklılık gösterebilmektedir. Antidepresan kaynaklı uyku bruksizmi ve hareket bozuklukları gibi daha az bilinen yan etkilerin daha iyi anlaşılması için prospektif çalışmalara ihtiyaç bulunmaktadır.

Keywords

antidepresan, cinsel disfonksiyon, nörolojik yan etki, tedavi uyumu, uyku bruksizmi

Supporting Institution

-

Project Number

-

Thanks

-

Comparison of antidepressant in terms of drug-related movement disorders and sexual side effects

Abstract

Purpose: The aim of this study was to compare different antidepressant groups regarding sexual side effects, sleep bruxism, and neurological side effects.
Materials and Methods: We included 406 patients between 18 and 50 years old, who were treated as an outpatient with a diagnosis of depressive disorders or anxiety disorders and had antidepressant monotherapy for more than one month. We applied sociodemographic data form, Hamilton Depression Scale (HDS), Hamilton Anxiety Scale (HAS), neurological side effects section of the UKU Side Effect Rating Scale, Arizona Sexual Experiences Scale (ASEX), and Morisky Medication Adherence Scale to all patients. We divided the antidepressants into three groups as selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI) and vortioxetine.
Results: The mean score of the UKU neurological side effects of those using SNRI in patients with GAD was significantly higher than those using SSRI. Adequate adherence to drug treatment was 91.3% for vortioxetine users, 73.8% for SSRI users, and 50% for SNRI users in patients with depressive disorder, and the difference between the three groups was statistically significant.
Conclusion: Antidepressant drug groups may differ from each other regarding some side effects and treatment adherence. Prospective studies are needed to understand better lesser-known side effects such as antidepressant-induced sleep bruxism and movement disorders.

Keywords

antidepressant, sexual dysfunction, side effects, bruxism

Project Number

-

References

• 1. Khawam EA, Laurencic G, Malone DA. Side effects of antidepressants: an overview. Clevel Clin J Med. 2006;73(4):351-3.
• 2. Bet PM, Hugtenburg JG, Penninx BWJH, Hoogendijk WJG. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–51.
• 3. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression. CNS Drugs. 2010;24(1):35–53.
• 4. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, DeVeaugh-Geiss A, Krebs EE, et al. Comparative risk for harms of second generation antidepressants. Drug Saf. 2008;31(10):851–65.
• 5. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64:5–12.
• 6. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants. Aust New Zeal J Psychiatry. 2009;43(9):795–808.
• 7. Bijlsma EY, Chan JSW, Olivier B, Veening JG, Millan MJ, Waldinger MD, et al. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014;121:88–101.
• 8. Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–78.
• 9. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006;91(1):27–32.
• 10. Doğan S. Cinsel işlev bozuklukları, depresyon ve antidepresanlar. J Mood Disord. 2011;1(2):81–6.
• 11. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants-a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010;22(3):148–56.
• 12. Shetty S, Pitti V, Babu CLS, Kumar GPS, Deepthi BC. Bruxism: a literature review. J Indian Prosthodont Soc. 2010;10(3):141–8.
• 13. Demir A, Uysal T, Guray E, Basciftci FA. The relationship between bruxism and occlusal factors among seven-to 19-year-old Turkish children. Angle Orthod. 2004;74(5):672–6.
• 14. Manfredini D, Lobbezoo F. Role of psychosocial factors in the etiology of bruxism. J Orofac pain. 2009;23(2):153–66.
• 15. Ferini-Strambi L, Pozzi P, Manconi M, Zucconi M, Oldani A. Bruxism and nocturnal groaning. Arch Ital Biol. 2011;149(4):467–77.
• 16. Albayrak Y, Ekinci O. Duloxetine-induced nocturnal bruxism resolved by buspirone: case report. Clin Neuropharmacol. 2011;34(4):137–8.
• 17. Uca AU, Uguz F, Kozak HH, Gümüs H, Aksoy F, Seyithanoglu A, et al. Antidepressant-induced sleep bruxism: prevalence, incidence, and related factors. Clin Neuropharmacol. 2015;38(6):227–30.
• 18. Garrett AR, Hawley JS. SSRI-associated bruxism: A systematic review of published case reports. Neurol Clin Pract. 2018;8(2):135–41.
• 19. Taycan SE, Kaya FD, Taycan O. Psikiyatri polikliniğine başvuran bir grup yaşlıda huzurevi ya da aile ile kalmanın depresyon ve anksiyete düzeyine etkisi. Klin Psikiyatr Derg. 2014;17(2):73–82.
• 20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Washington DC, American Psychiatric Pub, 2013.
• 21. Sateia MJ. International classification of sleep disorders-third edition. Chest. 2014;146(5):1387-94.
• 22. Ursavaş A. Yeni Uyku Bozuklukları Sınıflaması (ICSD-3) uykuda solunum bozukluklarında neler değişti. Güncel Göğüs Hast Serisi. 2014;2(2):139–51.
• 23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
• 24. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384–8.
• 25. Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı. Psikiyatr Psikol Psikofarmakol Derg. 1996;4(4):251–9.
• 26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-5.
• 27. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. Hamilton anxiety rating scale: interrater reliability and validity study. Turk Psikiyatr Derg. 1998;9(2):114–7.
• 28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987; 334:1-100.
• 29. Sağlam Aykut D. Şizofreni Hastalarında Hastalık Süresinin Klinik Özelliklere Etkisi. Klin Psikiyatr Derg. 2017;20(4):301–7.
• 30. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona sexual experience scale (ASEX): reliability and validity. J Sex &Marital Ther. 2000;26(1):25–38.
• 31. Soykan A. The reliability and validity of Arizona sexual experiences scale in Turkish ESRD patients undergoing hemodialysis. Int J Impot Res. 2004;16(6):531–4.
• 32. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;67–74.
• 33. Yılmaz S. Psikiyatri hastalarında ilaç yan etkileri ve ilaç uyumu (Yüksek lisans tezi). İstanbul, İstanbul Üniversitesi Sağlık Bilim Enstitüsü, 2004.
• 34. Castellucci LA, Shaw J, van der Salm K, Erkens P, Le Gal G, Petrcich W, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015;136(4):727–31.
• 35. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand. 2006;114(6):384–97.
• 36. Segraves RT. Sexual dysfunction associated with antidepressant therapy. Urol Clin North Am. 2007;34(4):575–9.
• 37. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61(4):276-81.
• 38. Lee K-U, Lee YM, Nam J-M, Lee H-K, Kweon Y-S, Lee CT, et al. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig. 2010;7(1):55-9.
• 39. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, et al. Sexual functioning assessed in 4 double-blind placebo-and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005;66(6):686-92.
• 40. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Psychology: Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4(4):917–29.
• 41. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036–48.
• 42. Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: a randomized, controlled trial. J Sex Med. 2019;16(10):1638–49.
• 43. Rajan R, Sun Y-M. Reevaluating antidepressant selection in patients with bruxism and temporomandibular joint disorder. J Psychiatr Pract. 2017;23(3):173–9.
• 44. Chang JP-C, Wu C-C, Su K-P. A case of venlafaxine-induced bruxism alleviated by duloxetine substitution. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):307.
• 45. Şahin OS, Malas FÜ. Duloxetine-induced sleep bruxism in fibromyalgia successfully treated with amitriptyline. Acta Reumatol Port. 2015;40(4):391-2.
• 46. Ay R, Aytas O. Acneiform eruption associated with the use of vortioxetine. Psychiatry Clin Psychopharmacol. 2019;29(2):226–8.
• 47. Revet A, Montastruc F, Roussin A, Raynaud J-P, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20(1):1–13.
• 48. Falisi G, Rastelli C, Panti F, Maglione H, Quezada Arcega R. Psychotropic drugs and bruxism. Expert Opin Drug Saf. 2014;13(10):1319–26.
• 49. Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015;49(10):1136–52.
• 50. Guo MY, Etminan M, Procyshyn RM, Kim DD, Samii A, Kezouh A, et al. Association of antidepressant use with drug-related extrapyramidal symptoms: A pharmacoepidemiological study. J Clin Psychopharmacol. 2018;38(4):349–56.
• 51. Mörkl S, Seltenreich D, Letmaier M, Bengesser S, Wurm W, Grohmann R, et al. Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. World J Biol Psychiatry. 2020;21(4):308–16.
• 52. Fenelon G. Antidepressants and movement disorders. In Medication-Induced Movement Disorders (Ed J Friedman):141-149. Cambridge, Cambridge University Press, 2015.
• 53. Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9(2):91-9.
• 54. Hansen HV, Kessing LV. Adherence to antidepressant treatment. Expert Rev Neurother. 2007;7(1):57–62.
• 55. Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS Drugs. 2017;31(5):421–32.